US EditionPublished • loading... • Updated
The Bosses that Decomplex the French Biotech
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Long perceived as a fertile scientific soil but unable to transform the trial at the commercial stage, France's biotech is changing in size. Thierry Abribat (Amolyt Pharma), Pierre d'Epenoux (ImCheck Therapeutics) and Marc de Garidel (Abivax) provide brilliant examples.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
